Regulators are now more often distinguishing between perceived good citizens and "bad actors" in stem cell and regenerative medicine clinical research, resulting in relatively more polar, carrot-and-stick oversight approaches. Here, I discuss why there may be too much carrot and not enough stick by regulators for effective enforcement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.stem.2018.06.004 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!